https://twitter.com/IrishCancerSoc/status/1858645024570802553
@mccarthymt7 With the General Election in Ireland approaching, I had a look through the @FineGael, @fiannafailparty and @labour party manifestos this evening as they relate to cancer services – so that you don’t have to (although feel free to look)!
Watch this dynamic roundtable discussion, hosted by Cancer Trials Ireland. Leaders in cancer research, patient advocacy, and politics come together to address critical issues in cancer trials and patient care.
Two hundred and ninety-six participants completed the survey.
Uptake of regular ASA or NSAIDs was modest at 34.8% and was even lower (25.7%) when focusing on individuals taking ASA or NSAIDs solely for chemoprevention of LS. More than half (55%) were taking <100 mg ASA daily.
Conclusion: Patient perceptions of the pros and cons of ASA, more so than demographic and disease-related factors, were associated with chemoprevention uptake.
Inaugural Event held this week.
The global status of genetic counsellors in 2023: What has changed in the past 5 years? https://www.sciencedirect.com/science/article/pii/S2949774424010331
Ireland is poorly served by the HSE in relation to the number of clinical geneticists and genetic counsellors.
In fact the HSE does not even recognise Genetic Counsellors. Are they not aware that Genetics and Genomics is the future and requires to be funded accordingly.
It is now possible to prevent cancer occurring rather than waiting for it to occur. From a cost perspective it is a “no brainer” to ensure that genomic integration in routine health care happens now.
Cancer patients, especially those who are receiving chemotherapy, have a much higher risk of DVT than other people.
MyLynch, a patient-facing clinical decision support(CDS) web application that applies genetically-guided personalised medicine(GPM) for individuals with Lynch syndrome.
As genetic panel testing becomes more widely available, GPM will play an increasingly important role in patient care, and CDS tools offer patients and providers tailored information to inform decision-making.
MyLynch provides personalised cancer risk estimates and interventions to lower these risks for patients with LS.
“Mainstreaming” is a proposed strategy to integrate genomic testing into oncology. The aim of this paper is to develop a mainstreaming oncogenomics model by identifying health system interventions and implementation strategies for mainstreaming Lynch syndrome genomic testing.
https://pubmed.ncbi.nlm.nih.gov/37305562/
Lynch Syndrome Ireland 